Biological particle type composite adjuvant and preparation method and application thereof
A technology of biological particles and adjuvants, applied in the biological field, can solve the problems of reduced diffusibility of adjuvants, easy diffusion, cytokine storm immune toxicity, etc., and achieve the effect of solving the toxic effect of adjuvants
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0032] This embodiment provides a biological particle type composite adjuvant, including bacteria-like particles of lactic acid bacteria and flagellin, the bacteria-like particles of lactic acid bacteria are the peptidoglycan backbone of lactic acid bacteria, and the flagellin passes through the peptidoglycan binding domain PA gene, The anchors are displayed on the surface of bacteria-like particles of lactic acid bacteria.
[0033] In this embodiment, the lactic acid bacteria is Lactococcus lactis, more specifically, Lactococcus lactis MG1363.
[0034] In this embodiment, the flagellin is the flagellin of Bacillus cereus, and the GenBank accession number of the Bacillus cereus is AE016877.1.
[0035] In this embodiment, the nucleotide amino acid sequence of the flagellin is shown in SEQ ID NO:1, and the amino acid sequence of the flagellin is shown in SEQ ID NO:2.
[0036] In this embodiment, the peptidoglycan binding domain PA gene is the C-terminal cell wall binding activi...
Embodiment 2
[0039]This embodiment provides the preparation method of the bioparticle type composite adjuvant as described in Example 1, comprising the following steps:
[0040] S1. Construction of recombinant flagellin comprising the peptidoglycan binding domain PA gene.
[0041] S2. Expressing and purifying the recombinant flagellin obtained in step S1.
[0042] S3, lactic acid bacteria are treated with hot acid to obtain bacteria-like particles containing only peptidoglycan skeleton;
[0043] S4. The recombinant flagellin obtained in step S2 is co-incubated with the bacteria-like particles obtained in step S3, and the PA gene of the peptidoglycan binding domain is bound to the surface of the bacteria-like particles to obtain a biological particle-type composite adjuvant.
[0044] In this embodiment, the specific process of constructing the recombinant flagellin containing the peptidoglycan binding domain PA gene in step S1 is as follows:
[0045] Synthesize the flagellin (BcFlg) gene ...
Embodiment 3
[0084] This example provides application examples and comparative examples of the above-mentioned bioparticle-type compound adjuvant vaccine.
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


